Chronic Hepatitis C: The Hidden Epidemic

Definition of the Problem
On August 17, 2012, the Centers for Disease Control and Prevention (CDC) released recommendations for testing all persons in the US born between 1945 and 1965 for hepatitis C infection.1 The Baby Boomer generation has been targeted because the CDC has determined that 75% of all chronic hepatitis C cases are between 47 and 67 years of age and the prevalence is five times higher in this age group than in any other.1

According to the Institute of Medicine, only 25% of those who are infected know their status and, given that there are an estimated 3.9 to 4.9 million persons living with hepatitis C virus (HCV) infection in the US, that means approximately 3 to 3.7 million American Baby Boomers currently have chronic hepatitis C and don’t know it.1,2 The majority of this group is believed to have been infected between 1980 and 1990, with an estimated 230,000 infections per year during that decade.4 By 1992, the year that sensitive assays for the identification of HCV were developed, the number of reported new cases had already declined by 78%, probably a result of a saturation of the drug-injecting population.5 The number of new cases has steadily declined each year since, and in 2010 there were only 17,000 new cases of acute infection.6,7 (more…)

Antifibrotic Protocolfor Hepatitis C

This story began 12 years ago, when I received a phone call from a prospective Canadian patient asking my advice about treating hepatitis C virus (HCV). He had acquired both hepatitis B and C infections from blood products used to treat hemophilia approximately 34 years earlier. Together we evaluated many claims of cure; tried promising remedies; and checked serum viral load, liver enzymes, and level of liver fibrosis. (Initially his biopsy revealed a level 3 cirrhosis, and FibroScan score >20.) Follow-up fibrosis studies were measured with the FibroScan. Years later his liver is now in the range of normal fibrosis (FibroScan 4.7). Remarkably, his serum HCV level was unchanged, still at 1 to 10 million copies/ml. (more…)

Coconut Oil Offers Hope for Antibiotic-Resistant Germs

Image of bacteriaby Brian and Marianita Shilhavy

I haven’t had a cold in over 5 years. Just when I feel as though I’m coming down with something, the scratchy, sore throat symptoms….gone the next morning! I also used to get these little blisters on the bottom of my right foot. Someone told me they are some sort of herpes virus. Since using the coconut oil I don’t get these annoying little things. Usually they would surface in the summer or when the weather turned warm. But I realized this fall that I hadn’t been bothered this past summer. I believe that the coconut oil really helps ward off the virus. I also have hepatitis C and my viral counts are so low that they are almost in the undetected category. I don’t even worry about this anymore. Nancy (more…)

CDC wants to go after all baby boomers with vaccines for a phantom virus

The Centers for Disease Control (CDC) is predicting an epidemic of hepatitis C (Hep-C) among baby boomers. So in order to preempt this epidemic, they have drafted a proposition to have everyone born between 1945 and 1965 tested for Hep-C in order to receive treatments and vaccinations (after diagnosis) with Hep-A and B vaccines.

That seems like a nasty proposition: two vaccinations that pretend to be designed for Hep-C. The Hep-B vaccine has an impressive track record of reported serious adverse reactions and deaths. They don’t have a Hep-C vaccination. Could it be because there is no virus?

Dr. Michael Tierra and Sepp Hasslberger report how Chiron, a diagnostic department of Novartis Vaccines, spent years struggling to find a Hep-C virus. After lots of manipulation the came up with footprint of a shadow, or a phantom virus, that enabled them to create a blood screening test for Hep-C that has made them a lot of money. (more…)

Natural bioflavonoids kill hepatitis C virus

Hepatitis C is an infectious disease of the liver that can cause miserable symptoms including fatigue, lack of appetite, abdominal pain, nausea and vomiting. Caused by a virus, hepatitis C affects about 200 million people worldwide. In the U.S. alone, one to two percent of the population is infected. Not only can this infectious disease cause scarring of the liver, cirrhosis, and eventually liver failure, but a significant number of people with hepatitis C also develop sometimes fatal liver disease or cancer.

The influence of hepatitis C infection activity on oxidative stress markers and erythropoietin requirement in hemodialysis patients.


We sought to expose the possible effect of hepatitis C virus (HCV) infection on oxidative stress indicators, nutritional status, and erythropoietin (rHuEPO) requirements in maintenance hemodialysis (MHD) patients. A total of 111 MHD patients (69 males, 42 females; mean age 51.3 +/- 13.0 years; MHD duration 78.5 +/- 52.1 months) and 46 healthy controls were enrolled in the study. We excluded patients with hepatitis B infection or malignancy. Indicators for oxidative status were studied in plasma samples obtained at the beginning of a clinically stable MHD session. Measurements were performed for plasma superoxide dismutase, glutathione peroxidase (antioxidative agents), and malonyldialdehyde (MDA; oxidative agent) by spectrophotometric methods. All patients were analyzed for the presence of anti-HCV; positive patients were also evaluated for the presence of HCV RNA. MHD patients were divided into three groups according to HCV infection status: group I (anti-HCV-positive, HCV-RNA-negative; n = 22); group II (anti-HCV-positive, HCV-RNA-positive; n = 22), and group III (anti-HCV-negative; n = 67). According to the analyses, MHD patients showed higher plasma oxidative stress indicators and lower antioxidative indicator levels compared to controls (P < .0001). MHD patients also displayed lower albumin and higher C-reactive protein (CRP) levels compared to controls (P < .0001). Antioxidant levels were decreased significantly from group I to III (P < .0001). MDA levels significantly increased from group I to III (P < 0.01). HCV-RNA-positive patients showed lowest albumin and highest CRP levels and rHuEPO requirements. Although alanine transferase (ALT) levels were in the normal range, group II patients had significantly higher ALT levels than the other groups (P < .01). In conclusion, we observed negative effects of active HCV infection on oxidative stress and rHuEPO requirements. In contrast, we detected that clinically inactive HCV infection was associated with reduced oxidative stress and rHuEPO requirements compared with active HCV infection and HCV-negative patients.

PMID: 20620489 [PubMed – indexed for MEDLINE]

Tutal E, Sezer S, Ibis A, Bilgic A, Ozdemir N, Aldemir D, Haberal M.

Department of Nephrology, Baskent University Hospital, Ankara, Turkey.